Helpful Guide,Outsourcing Facilities Association

A significant legal battle is unfolding between the Outsourcing Facilities Association (OFA), a prominent trade group representing compounding pharmacies, and the U.S. Food and Drug Administration (FDA). At the heart of this dispute is the FDA's decision to remove semaglutide, a crucial component in popular weight-loss and diabetes medications like Ozempic and Wegovy, from its official drug shortage list. This action has triggered multiple lawsuits filed by the OFA and its members, alleging that the FDA acted "recklessly and arbitrarily."

The core of the lawsuit centers on the OFA's assertion that despite the FDA's declaration, semaglutide supply issues persist. The association contends that the FDA prematurely removed semaglutide from the shortage list, thereby impacting outsourcing facilities that have been legally compounding the drug. These outsourcing facilities, operating under section 503B, were compounding semaglutide in compliance with federal law, with their activities directly regulated by the FDA. However, the FDA's recent decision has created uncertainty and legal challenges for these entities.

The legal challenges have seen various rulings and developments. In a significant ruling on April 25, 2025, a federal court denied the Outsourcing Facilities Association's motion for a preliminary injunction, which would have prevented the FDA from taking action against compounders. This ruling, along with others in March 2025, has largely upheld the FDA's decision to remove semaglutide from the shortage list. A Texas federal court has also ruled in favor of the FDA in cases brought by the OFA and other drug compounders. These court decisions suggest that the grace period for 503B outsourcing facilities to compound semaglutide injectable drugs may expire, as seen with a reported expiration date of May 22, 2025.

The OFA's arguments in its lawsuits include claims that the FDA acted recklessly in removing semaglutide from the shortage list without adequate consideration of the ongoing supply chain complexities. The association believes the FDA's action was not based on a comprehensive analysis of the market and that shortages of the drug continue to exist. This perspective is further emphasized by the fact that semaglutide's removal from the FDA shortages list has also set the stage for potential further legal actions by the drug's manufacturer, Novo Nordisk, against unauthorized compounded versions.

Despite the legal setbacks, the Outsourcing Facilities Association has continued to pursue its challenges. In February 2025, the OFA filed a lawsuit against the U.S. Food and Drug Administration (FDA), specifically challenging the agency's decision regarding semaglutide. This followed a similar lawsuit filed in October of the previous year after the FDA made a similar determination regarding tirzepatide. The lawsuit brought by the Outsourcing Facilities Association alleged that the FDA acted unreasonably in its removal of semaglutide from the shortage list and sought to have this decision declared unlawful and reversed.

The legal actions highlight a broader conflict between the FDA's regulatory oversight, the manufacturer's intellectual property rights, and the role of compounding pharmacies in addressing drug shortages. While the FDA maintains its decisions are based on available data and regulatory frameworks, the OFA and its members argue for a more nuanced approach that acknowledges the realities of drug availability and the vital role of outsourcing facilities in patient care. The ongoing legal proceedings and evolving court rulings will continue to shape the landscape for semaglutide compounding and the regulatory environment for outsourcing facilities. The association is seeking to ensure that outsourcing facilities can continue to provide necessary compounded medications while adhering to all federal regulations. The Outsourcing Facilities Association's persistent legal efforts underscore their commitment to advocating for their members and for patient access to medications. The legal outcome of the semaglutide case will set important precedents for future lawsuits involving drug shortages and the FDA's regulatory actions.